News & Presentations

A scalable and flexible future for gene therapy production
November 1, 2021

3:00pm ET

More Information>

Umoja Biopharma Appoints Biotech Industry Leader Clay Siegall, Ph.D. as Chairman of the Board
October 18, 2021

Seattle, Wash., October 18, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointment of Clay Siegall, Ph.D. as its Chairman of the Board of Directors.

READ MORE >

Integrating in vivo Transduction of CARs with Universal Solid Tumor Targeting Molecules
September 1, 2021

12:30pm ET

More Information>

Preclinical Modeling of in vivo Engineered CAR-T Products
August 31, 2021

4:45pm ET

More Information>

Umoja Biopharma Breaks Ground on Extensive Manufacturing Facility for its Next-Generation CAR T Immunotherapies
August 30, 2021

Seattle, Wash., August 30, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the groundbreaking of its new development and manufacturing facility in Louisville, Colo. Construction of the state-of-the-art facility is a key milestone for the company and represents an important next step in bringing effective and accessible CAR T therapies to cancer patients.

READ MORE >

We are led by a world class team that operates on a foundation of respect for the contributions of everyone on the Umoja team.